ACTRN12620001178932已完成1 期
A Phase 1, open label, single dose, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of EARLI-001 in subjects with locally advanced or metastatic lung cancer or subjects with metastases in the lung or liver of a primary cancer origin other than lung cancer
Earli, Pty Ltd0 个研究点目标入组 10 人开始时间: 2020年11月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Diagnosis
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Signed written informed consent prior to the initiation of any study-specific procedures.
- •2. Males and females aged 18 years or older at time of consent
- •3. Histologically or cytologically confirmed locally advanced or metastatic lung cancer. Subjects with metastases in the lung or liver of a primary cancer origin other than lung cancer may also be considered for inclusion
- •4. Expected survival greater than 3 months
- •5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •6. Body mass index (BMI) less than or equal to 32.0 kg/m2
- •7. Adequate organ and marrow function based on clinical laboratory assessments
- •8. Female subjects must be of non-childbearing potential
- •9. Male patients must use highly effective contraception methods consisting of 2 forms of birth control starting at screening and continuing throughout the study period and for 3 months after the last study treatment
排除标准
- •1. Females of child-bearing potential or who are breastfeeding or who have a positive pregnancy test
- •2. Has a known severe hypersensitivity to any of the excipients in the formulation of EARLI-001.
- •3. Has a clinically significant history or presence of ECG findings as judged by the PI or designee at screening
- •4. Has received treatment within 30 days or 5 half-lives (whichever is greater) before dosing for their current diagnosis of histologically or cytologically confirmed locally advanced or metastatic lung cancer or their current diagnosis with metastases in the lung or liver of a primary cancer origin other than lung cancer. Subjects will be permitted to start on an approved treatment after the Day 8 assessments have been completed.
- •5. Has received treatment with another investigational drug, or investigational device, within 30 days or 5 half-lives (whichever is longer) before dosing.
- •6. Is currently taking heparin, or a heparin analog.
- •7. Has signs or symptoms of organ failure, major chronic illnesses other than cancer, or any concomitant medical or social conditions which, in the opinion of the investigator, make it undesirable for the patient to participate in the study, or which could jeopardize compliance with the protocol.
- •8. Is unable to cooperate fully with the requirements of the study protocol, including the schedule of assessments, or likely to be non-compliant with any study requirements
- •9. Other unspecified reasons that, in the opinion of the PI or Sponsor, make the patient unsuitable for enrollment.
研究者
相似试验
已完成
1 期
A clinical trial to assess the safety of new erythropoietin in chronic kidney disease patients on Haemodialysis.CTRI/2011/11/002153Serum Institute of India Pvt Ltd40
终止
1 期
A Phase I Open-Label, Single Dose, Dose Escalation Study of KB002, a Chimeric Monoclonal Antibody Which Binds to GM-CSF (Granulocyte Macrophage Colony Stimulating Factor), in Patients with Chronic Idiopathic Thrombocytopenia Purpura (ITP)Idiopathic Thrombocytopenia Purpura (ITP)Blood - Other blood disordersACTRN12606000459527KaloBios Pharmaceuticals Inc27
已完成
1 期
A BA/BE study to evaluate the safety, tolerability of endoxifen in healthy human subjectsCTRI/2009/091/000625ambda Therapeutic Research Ltd40
已完成
1 期
An open label, single arm, dose escalation phase 1 trial of PRI-724 in patients with HCV-induced cirrhosisHepatitis C virus-induced cirrhosisJPRN-UMIN000014395Tokyo metropolitan Komagome Hospital16
未知
1 期
A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast CancerJPRN-jRCT2080220921AstraZeneca